Tumour marker measurements in the diagnosis and monitoring of breast cancer.
about
Simultaneous detection of nucleic acid and protein using gold nanoparticles and lateral flow devicePrognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.Do serum biomarkers really measure breast cancer?Chemopreventive Activity of Honokiol against 7, 12 - Dimethylbenz[a]anthracene-Induced Mammary Cancer in Female Sprague Dawley Rats.Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour markerMultiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.Early detection of recurrent breast cancer using metabolite profiling.Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.Current approaches and challenges in monitoring treatment responses in breast cancer.The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies.Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.Occult breast cancer presenting as metastatic adenocarcinoma of unknown primary: clinical presentation, immunohistochemistry, and molecular analysisSerum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics.Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancersClinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.Prognostic factors for patients with hepatic metastases from breast cancer.Serological diagnosis of liver metastasis in patients with breast cancer.A upconversion luminescene biosensor based on dual-signal amplification for the detection of short DNA species of c-erbB-2 oncogene.Serum Tumor Marker Use in Patients With Advanced Solid Tumors.Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion.Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.Role of circulating tumor cells and disseminated tumor cells in primary breast cancer.Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer.Serum tumor markers and PET/CT imaging for tumor recurrence detection.Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.Phototoxic aptamers selectively enter and kill epithelial cancer cells.Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer.CA15.3, CEA and LDH in dogs with malignant mammary tumors.Combination of plasma HA and circulating M2-like monocytes may serve as a diagnostic marker for breast cancer.Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT?: results from small population with previous breast cancer.TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer.Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
P2860
Q30434294-D936F24C-106B-4463-B04F-8E22AB5F3011Q33237573-42EF248D-D9CF-46D8-B5C9-E55582877CA0Q33454967-5378916C-0EBD-44A1-8598-0D780E009DE5Q33742294-760DF7D9-AF85-4F86-9581-4C4705BB2CBCQ33831823-2888D452-B28D-41AC-BBFD-709EA4DA169AQ33888119-4E336F09-482D-4BEC-A96C-29A16E958E84Q34093465-D3DDF38C-CF81-48B5-9356-5B0869502A20Q34348721-D664AC04-A4FC-4A41-BB91-F1329103A833Q34369288-3EA382D9-8618-410B-B84A-AF10BD1557BAQ34646288-F1402B33-EECA-452B-A418-A7568B489C12Q34658727-7C8133E8-FA84-4735-86E7-51793C6A2436Q35090470-789A1359-BE7B-4A55-BE46-12DD286A80A6Q35776220-AD5635E0-C232-49E4-A289-7B43692986BEQ35789437-D7C84FFF-2F30-442F-BDB2-AFD66374AEF6Q35839007-81707432-AFE0-4832-9A59-7389713619A0Q36477512-F8EC883A-C14C-412F-A722-80A6E79B0B0CQ36591915-00CC2611-9410-480F-B563-A43B801799C0Q36646442-11E62B93-FC38-4BE8-A998-E994B098CADEQ36648280-06E4D92A-DB4C-4B94-99FE-101BCA04DC29Q36670910-73379FCE-FA4C-41D7-BEDF-B2B07BE930E1Q36814331-2CBF41F7-141E-4D60-B48F-B1AEB9A844B6Q36819605-E56AA051-B188-4CA0-A3AD-325229C3ABEEQ37157669-8D10228C-808A-43FE-8DEA-72623373221DQ37175071-3BFF1C21-F6AD-4CF5-AF9B-73FDC4D578C7Q37341686-B362BD5F-2FEA-46DD-AC5A-0737C75D5465Q37386179-66DED4C1-6ED0-4950-9EA1-D7062D0070E2Q37885239-C6F2EB9D-7136-4DF7-880B-0DAD5B26EAA5Q38027590-829D452C-69EB-4272-9CF0-F2166AA41461Q38082682-B1FA166C-A09F-4DBA-B9FF-46253E3991F1Q39147491-E5901500-481E-40E2-B6B1-D8916F49E420Q39902348-35F18FCE-E1D9-4ADF-8FCA-B46405ABCAECQ40232992-6B505030-5058-4BC5-B381-2D615CC5D395Q43462217-2FD95A62-97CD-4111-B0C7-76FB83C31389Q43648582-D5DD9CDB-FD24-46E4-AD84-CEECCF43320BQ44915628-EB336F49-FB12-48BB-BD60-4073C76E40B5Q46536279-696997F5-37C2-4DCD-83F5-209CC1500EA2Q47158945-2EF6D790-B65D-4F55-A5D4-6C8380E0FE05Q47552039-119E0CBC-B714-4E08-9C23-5B8553F0379CQ49382293-712C9459-FF14-4B3F-AB46-103334EF4B03Q49399828-23916B71-E685-44DE-BAB0-FC5B3C6BA58F
P2860
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@ast
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@en
type
label
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@ast
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@en
prefLabel
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@ast
Tumour marker measurements in the diagnosis and monitoring of breast cancer.
@en
P356
P1476
Tumour marker measurements in the diagnosis and monitoring of breast cancer
@en
P2093
Robertson JF
P304
P356
10.1053/CTRV.1999.0151
P577
2000-04-01T00:00:00Z